Go to the Seeking Alpha website and pull up the article. It is a very good read, and his biggest worry, a cash raise, has already occurred due to the many upcoming trials this year.
Samreen Agha

Small-cap, value, growth, healthcare

Idera Pharmaceuticals Going Into 2015
Dec. 22, 2014 2:57 PM ET | 15 comments | About: Idera Pharmaceuticals, Inc. (IDRA)
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
Summary
•Idera has an exciting year ahead based on number of important developments.
•Positive clinical data on IMO-8400 and IMO-2055, will result in clinical advancement.
•Development in the GSO program will garner increased investor attention, as it holds promise and potential.
•These activities will increase the need for additional funds, which may result in dilutive stock offering, if a partnership is not achieved.
•I remain bullish on Idera, and expect the stock to add significant shareholder value in 2015.

Biotech is NOT overbought. Biotech is where the most progress in discovery and revenue generation is made, and also where the most M&A activity has been for the past couple of years. You can't put your money into oil or commodities. Staples and consumer goods aren't going to give you much of a return, and if there is a downturn in the economy those stocks go down too. Biotech still offers the best potential gains, and large gains at that.

Clueless is the definition of someone like you brettie who thinks they know anything about a company just because of the movement of the stock price. That is just plain idiocy. You know Apple lost more than half it's value at one point and so did Google? You still haven't told ANYONE here ONE THING you know about IDRA-----only about whether the stock is going down-----and you say the same thing every day---just like a little parrot. The longs here understand the company and the science, and the significance of the discoveries that they have made and are progressing with and are willing to stay through some down market days to see the longer term growth of this company and the stock. What is your thesis brettie? You are only shorting to be short---that's it---plain and simple and for no other reason----and that is what a fool does. If you have made ANY money on IDRA it just shows that you have been a lucky fool since you can not comprehend what this company is about. That's it.

It was never mentioned at all to have any partnerships with 8400, 9200, and the GSO's. The partnership/collaboration element comes in with the combination therapy of 2125/2055 and rituximab/ipilumimab. Since the company stated that they INTEND to have trials UNDERWAY in 6-9 months with combination therapy it is expected that partnerships would be formed.

The overall market seems to be weakening, but IDRA has moved back up a bit. IDRA has had quite a few of these paradoxical moves, and many buyers may see the opportunity here supported by the stock moving back up from the low today in a weak market.

Well---you already know what I DID! I kept adding all the way down and built up my position. NOW---if I want, I can trade for some extra gains. Since I also have my shares in retirement accounts and will not be retiring for at least a few years, the short term drops are something I can take(and as a biotech veteran I've taken plenty of them) while looking to possibly trade or add on the dips. If you can't take it, then small-cap biotech is not a good place for your money. You have to be able to commit and at least let a core position sit for a little while, or be able to add when the opportunity presents. Following the secondary and the strength shown by the stock holding up very well, I think any dips will be smaller in magnitude and shorter in duration since we all know what is on the agenda for this year. If you are confident like I am in the stock rising this year and being substantially higher later this year, then there is no problem either holding here or adding. Trading a stock like this is very tricky, risky(because they can turn on a dime), and nerve-racking. That's the best I can give you.

I think that's a good idea----I will also have an order for another 5000 shares there---but I don't think either of us will get a fill. After 2 conferences there is a chance that at least one upgrade will be coming, and if it does then the price goes above $5 to stay and higher from there. Even without that, IDRA is headed higher throughout the year.

Brett----if you can name one "tute" that "dumped" I would be floored. Here is my reply to you again:
Brettie(and now "Vancouver-HAHA)----I have no problem with anyone "questioning" this stock. But you are not questioning...
by mgm2020 • Feb 27, 2015 9:33 PM Remove
.the stock at all. All you are doing is making pointless, baseless, and incorrect statements that have absolutely no rational basis except for "because I said so". But I guess you're used to that since that's what your mommy says to you when it's time to go to bed and you don't WANT to go to bed, or time to take a bath and you just took a bath a week ago, or time to turn off the computer because you are going to those "bad" web sites again, or time to pick your clothes up off the floor and you can't figure out where they go. You have NEVER offered a VALID reason why this stock will not succeed, other than you saying that you are shorting(which none of us believe anyway). But you saying you're shorting the stock has nothing to do with the company's success-----but it does highlight your ability to pick the wrong side to bet on. Tell us if you can: What is wrong with the science? What do you know about TLR's and GSO's that has you convinced that they will not succeed? Why won't MIlano succeed with IDRA like he did with VRPH? Why did the preclinical studies with IMO-2125 and IMO-2055 along with ipilumimab and rituximab show such potent and statistically significant anti-tumor activity yet you don't think that is significant? How is $130 million in the bank not going to help the company achieve it's objectives and WHY would the Baker Brothers buy another 5.3 million shares and the CEO buy 200,000 shares of the stock? If you can't answer any of these questions with a logical, rational reply then do us all a favor-----and just LEAVE, because I will repost this on every single one of your posts so EVERYONE can see how full of QRAP you are. We are all anxiously awaiting your wisdom

will it reach $7?? $8?? I was in TROV 2 years ago when it hit $11------and the advancements since then have been nothing short of remarkable. As I have stated before---TROV should have a market cap of at least $300-$500 million, which would translate to a stock price of $15-$25-------and that market cap is very conservative for the potential value of this platform.

to see what's going on here. Volume has been consistently strong on a nice move up following the secondary, a large fund that has a $6.25 price target and buys at the secondary decides to ADD another 230,000 shares at a price 15-20% higher and nearly AT their price target, the market is realizing that while the secondary put a considerable amount of cash in the bank the float is still very small, and the testing process is coming to a climax and it's nearly time to roll out the platforms----which will be hugely successful. Did I miss anything? Oh yeah-----this company would maker an EXCELLENT acquisition!

Trending Tickers

i

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.

Yahoo! Finance Worldwide

Quotes are real-time for NASDAQ, NYSE, and NYSEAmex when available. See also delay times for other exchanges. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.